Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / APRE - Aprea on go with early-stage study with APR-548 in blood disorder

APRE - Aprea on go with early-stage study with APR-548 in blood disorder

Aprea Therapeutics Inc.
The FDA has signed-off Phase 1 trial of Aprea Therapeutics's (APRE) APR-548 for the treatment of TP53 mutant myelodysplastic syndromes.APR-548 is a small molecule reactivator of mutant p53 that is being developed for oral administration.

For further details see:

Aprea on go with early-stage study with APR-548 in blood disorder
Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...